MONTREAL, Sept. 13, 2023 (GLOBE NEWSWIRE) -- DalCor Pharmaceuticals today announced the closing of the company™s Series D financing round of $80m USD to conduct the Dal-GenE-2 confirmatory trial in...
DalCor Pharmaceuticals has regrouped from past setbacks to complete an $80 million Series D round to advance its cholesteryl ester transfer protein (CETP) inhibitor, dalcetrapib, to Phase III for reducing myocardial infarction.
LONDON and MONTREAL, Jan. 11, 2021 (GLOBE NEWSWIRE) -- DalCor Pharmaceuticals today announced the initiation of dal-COVID, a Phase 2 proof-of-concept study for dalcetrapib as a potential oral anti-viral treatment for COVID-19.